Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Biotech Chutes & Ladders—CRISPR Therapeutics finds new CMO in Sanofi leader By Gabrielle Masson, Andrea Park May 24, 2024 8:30am Chutes and Ladders CRISPR Therapeutics Sanofi Novartis ...

The financing effort, spearheaded by Goldman Sachs and Morgan Stanley, forms part of Sanofi’s strategy to divest its $20 billion consumer health business.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other ...

Sanofi blamed the primary endpoint miss on “the nature of this limited phase 2 study.” Efficacy levels were “comparable to other oral medicines in psoriasis,” according to the company, and ...

Sanofi is conducting a broad strategy review under Hudson, who took over as CEO on Sept. 1. He will give initial pointers on which businesses he wants to focus on at the investor day in Cambridge ...

– Bolsters clinical pipeline and adds near-term value creation opportunities – – Licenses proprietary masking platform with goal of minimizing off-tumor toxicity and offering expanded ...

Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the purchase of Cambridge-based Genzyme Corp. for $20.1 billion and will lead the company to further ...